MRSN insider trading
NasdaqGS HealthcareMersana Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. As of January 6, 2026, Mersana Therapeutics, Inc. operates as a subsidiary of Day One Biopharmaceuticals, Inc.
Company website: www.mersana.com
MRSN insider activity at a glance
FilingIQ tracks 450 insider transactions for MRSN in filings since Jul 6, 2017. The most recent transaction is dated Jan 6, 2026.
Across the full history, 35 open-market purchases
and 113 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on MRSN insider trades is 56.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest MRSN Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for MRSN?
- FilingIQ tracks 450 Form 4 insider transactions for MRSN (Mersana Therapeutics, Inc.), covering filings from Jul 6, 2017 onwards. 0 of those are dated within the last 90 days.
- Are MRSN insiders net buyers or net sellers?
- Across the full Form 4 history for MRSN, 35 transactions (8%) were open-market purchases and 113 (25%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does MRSN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is MRSN in?
- Mersana Therapeutics, Inc. (MRSN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $145.36M.
Methodology & sources
Every MRSN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.